Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.71 | -$12.78 | -54.41% | 844.5K | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $6.00 | -$2.91 | -32.66% | 118.5K | $422M | $2.51$48.91 |
| PFSA | Profusa | $3.11 | -$1.26 | -28.87% | 285.2K | $378M | $2.90$957.00 |
| VHUB | VenHub Global | $3.52 | -$1.31 | -27.12% | 475.2K | $362M | $3.40$40.30 |
| FLYE | Fly-E Group | $2.55 | -$0.91 | -26.30% | 237.1K | $5.6M | $2.50$161.80 |
| MNDY | Monday.com | $76.42 | -$21.58 | -22.02% | 349.2K | $5.0B | $73.01$342.64 |
| PGY | Pagaya Technologies | $14.77 | -$3.87 | -20.76% | 680.7K | $1.5B | $8.50$44.99 |
| RDIB | Reading International | $10.79 | -$2.67 | -19.84% | 27.3K | $306M | $5.81$17.40 |
| HIMS | Hims & Hers Health | $18.53 | -$4.49 | -19.50% | 3M | $5.2B | $16.36$72.98 |
| CLF | Cleveland-Cliffs | $12.22 | -$2.52 | -17.07% | 1.9M | $8.4B | $5.63$16.70 |
| MPAA | Motorcar Parts Of America | $10.96 | -$2.18 | -16.59% | 8.9K | $257M | $6.04$18.12 |
| SXTC | China Sxt Pharmaceuticals | $2.55 | -$0.46 | -15.17% | 4.4M | $2.6M | $2.34$1,176.00 |
| MAXN | Maxeon Solar Technologies | $3.32 | -$0.57 | -14.65% | 439.3K | $66M | $2.46$6.02 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $32.98 | -$4.80 | -12.71% | 1.7M | - | $19.91$75.28 |
| ONEG | OneConstruction Group | $4.29 | -$0.62 | -12.63% | 91.4K | $79M | $1.00$13.50 |
| IBG | Innovation Beverage Group | $4.20 | -$0.59 | -12.24% | 49.8K | $3.3M | $3.27$49.25 |
| WAT | Waters | $336.41 | -$44.88 | -11.77% | 84.7K | $23B | $275.05$414.15 |
| ALX | Alexander's | $226.18 | -$28.89 | -11.33% | 237.8K | $1.3B | $189.05$260.84 |
| OBAI | Tg-17 | $17.50 | -$1.50 | -7.89% | 10.2K | $61M | $16.54$38.50 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
